DAPA-CKD: Significant Victory for CKD with or without Diabetes
{{output}}
Sodium glucose cotransporter 2 inhibitors (SGLT2i) have revolutionized the treatment of heart failure and diabetic kidney disease. The DAPA-CKD trial by Heerspink et al. evaluated primary kidney outcomes with dapagliflozin in both diabetic and non-diabetic pat... ...
